These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 23463968

  • 1. Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure.
    Hori M.
    Future Cardiol; 2013 Mar; 9(2):163-76. PubMed ID: 23463968
    [Abstract] [Full Text] [Related]

  • 2. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T.
    Cardiovasc Drug Rev; 2007 Mar; 25(1):1-13. PubMed ID: 17445084
    [Abstract] [Full Text] [Related]

  • 3. Hyponatremia, heart failure, and the role of tolvaptan.
    O'Connell JB, Alemayehu A.
    Postgrad Med; 2012 Mar; 124(2):29-39. PubMed ID: 22437213
    [Abstract] [Full Text] [Related]

  • 4. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C, Hutchinson DJ.
    Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
    [Abstract] [Full Text] [Related]

  • 5. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.
    Hauptman PJ, Burnett J, Gheorghiade M, Grinfeld L, Konstam MA, Kostic D, Krasa HB, Maggioni A, Ouyang J, Swedberg K, Zannad F, Zimmer C, Udelson JE, Everest Investigators.
    J Card Fail; 2013 Jun; 19(6):390-7. PubMed ID: 23743487
    [Abstract] [Full Text] [Related]

  • 6. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
    Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C, Tolvaptan Investigators.
    Circulation; 2003 Jun 03; 107(21):2690-6. PubMed ID: 12742979
    [Abstract] [Full Text] [Related]

  • 7. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
    Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Kodama M, Aizawa Y.
    Biochem Pharmacol; 2008 Mar 15; 75(6):1322-30. PubMed ID: 18179782
    [Abstract] [Full Text] [Related]

  • 8. Treatment options for hyponatremia in heart failure.
    Goldsmith SR.
    Congest Heart Fail; 2010 Jul 15; 16 Suppl 1():S15-8. PubMed ID: 20653706
    [Abstract] [Full Text] [Related]

  • 9. Tolvaptan for the treatment of hyponatremia and congestive heart failure.
    Ferrer E.
    Drugs Today (Barc); 2010 Mar 15; 46(3):163-71. PubMed ID: 20467590
    [Abstract] [Full Text] [Related]

  • 10. Hyponatremia in hospitalized patients: the potential role of tolvaptan.
    Deitelzweig SB, McCormick L.
    Hosp Pract (1995); 2011 Aug 15; 39(3):87-98. PubMed ID: 21881396
    [Abstract] [Full Text] [Related]

  • 11. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
    Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C, SALT Investigators.
    N Engl J Med; 2006 Nov 16; 355(20):2099-112. PubMed ID: 17105757
    [Abstract] [Full Text] [Related]

  • 12. Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.
    Veeraveedu PT, Palaniyandi SS, Yamaguchi K, Komai Y, Thandavarayan RA, Sukumaran V, Watanabe K.
    Drug Discov Today; 2010 Oct 16; 15(19-20):826-41. PubMed ID: 20708094
    [Abstract] [Full Text] [Related]

  • 13. The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists.
    Ghali JK, Tam SW.
    J Card Fail; 2010 May 16; 16(5):419-31. PubMed ID: 20447579
    [Abstract] [Full Text] [Related]

  • 14. Hyponatremia in heart failure: the role of arginine vasopressin and its antagonism.
    Rosner MH, Ronco C.
    Congest Heart Fail; 2010 Jul 16; 16 Suppl 1():S7-14. PubMed ID: 20653716
    [Abstract] [Full Text] [Related]

  • 15. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
    Onogawa T, Sakamoto Y, Nakamura S, Nakayama S, Fujiki H, Yamamura Y.
    Cardiovasc Drugs Ther; 2011 Dec 16; 25 Suppl 1():S67-76. PubMed ID: 22120095
    [Abstract] [Full Text] [Related]

  • 16. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
    Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Suzuki K, Kodama M, Aizawa Y.
    Biochem Pharmacol; 2007 Nov 15; 74(10):1466-75. PubMed ID: 17720144
    [Abstract] [Full Text] [Related]

  • 17. Vasopressin dysregulation: hyponatremia, fluid retention and congestive heart failure.
    LeJemtel TH, Serrano C.
    Int J Cardiol; 2007 Aug 09; 120(1):1-9. PubMed ID: 17346825
    [Abstract] [Full Text] [Related]

  • 18. [Vasopressin V2-receptor antagonist, tolvaptan, for treatment of heart failure].
    Yamamura Y, Sato O, Fujiki H.
    Nihon Rinsho; 2007 May 28; 65 Suppl 5():164-8. PubMed ID: 17571379
    [No Abstract] [Full Text] [Related]

  • 19. Management of hyponatremia in heart failure: role of tolvaptan.
    Albert NM, Chase S.
    J Cardiovasc Nurs; 2013 May 28; 28(2):176-86. PubMed ID: 22635058
    [Abstract] [Full Text] [Related]

  • 20. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.
    Wong F, Blei AT, Blendis LM, Thuluvath PJ.
    Hepatology; 2003 Jan 28; 37(1):182-91. PubMed ID: 12500203
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.